attract
target
develop
therapeut
sar
due
fundament
role
viral
mcmaster
high
throughput
screen
laboratori
depart
biochemistri
replic
homolog
model
pro
xray
crystallographi
recent
mutagenemcmast
univers
hamilton
ontario
si
studi
identifi
pro
cystein
proteas
cyshi
catalyt
dyad
activ
site
canada
depart
microbiolog
biochemistri
structurebas
sequenc
align
sarscov
equival
polyprotein
univers
british
columbia
vancouv
british
columbia
human
coronaviru
hcov
porcin
transmiss
gastroenter
viru
tgev
bovin
coronaviru
canada
bcov
avian
infecti
bronchiti
viru
ibv
identifi
consensu
sequenc
proteolysi
v
p
l
v
f
q
g
n
c
vitro
summari
studi
confirm
abil
pro
process
site
type
proteinas
highest
caus
agent
sever
acut
respiratori
syndrom
sar
identifi
novel
coronavispecif
cleavag
site
flank
pro
polyprotein
ru
sarscov
main
proteinas
sarscov
pro
attract
target
therapeut
structur
model
pro
base
sequenc
homolog
tgev
well
solv
crystal
sar
owe
fundament
role
viral
replic
sought
identifi
novel
inhibitor
pro
adstructur
use
number
studi
dock
substrat
mimic
virtual
vanc
develop
appropri
therapi
treatment
sar
pro
clone
express
screen
collect
synthet
compound
natur
product
approv
antivir
therapi
evalupurifi
isol
quench
fluoresc
reson
energi
transfer
assay
devel
abil
inhibit
pro
compound
identifi
potenti
inhibitor
pro
ope
pro
screen
proteinas
druglik
small
molecul
fulli
autom
sysstudi
includ
proteas
inhibitor
revers
transcriptas
inhibitor
calanolid
tem
primari
screen
identifi
hit
seri
virtual
experiment
filter
number
nevirapin
glycovir
inhibitor
sabadinin
natur
product
gener
reduc
five
novel
small
molecul
show
potent
inhibitori
activ
ic
toward
antivir
ribavirin
ribavirin
shown
exhibit
antisarscov
activ
vitro
concentra
reemerg
iti
sar
guangdong
provinc
china
decemsever
vitro
screen
also
recent
reber
spring
necesport
assess
abil
exist
proteinsarili
indic
anoth
global
outbreak
illustr
ase
inhibitor
inhibit
replic
sarscov
need
continu
effort
studi
viru
dein
case
pro
specif
proteas
velop
appropri
therapeut
treatment
inhibitor
indinavir
saquinavir
ritonavir
lopinavir
sarscov
envelop
positivestrand
rna
shown
ineffect
inhibviru
whose
genom
predomin
two
open
readit
replic
sarscov
vitro
anoth
ing
frame
connect
ribosom
frameshift
proteas
inhibitor
nelfinavir
shown
inhibit
site
encod
two
replicas
protein
sarscov
replic
ec
nm
yet
polyprotein
cleav
also
report
complet
inhibit
viral
main
proteinas
pro
also
call
pro
replic
seen
compound
concentr
anoth
vitro
screen
similarli
correspond
ebrown
mcmasterca
edb
lelti
interchang
test
librari
proteas
inhibitor
result
ubcca
lde
author
contribut
equal
work
one
compound
inhibit
pro
molecul
develop
transitionst
analog
inhibitor
proteas
k
pro
although
number
exist
drug
could
potenti
act
inhibitor
pro
identifi
virtual
screen
ribavirin
known
activ
compound
actual
toward
proteas
addit
vitro
screen
campaign
illustr
exist
proteas
inhibitor
two
identifi
activ
toward
pro
find
illustr
need
look
toward
develop
innov
inhibitor
proteas
one
studi
recent
identifi
uniqu
ketoglutamin
analog
inhibitor
pro
ic
low
micromolar
rang
jc
vedera
submit
effort
advanc
initi
sought
identifi
novel
small
molecul
specif
target
pro
paper
describ
clone
express
purif
pro
sarscov
isol
subsequ
order
screen
sarscov
pro
librari
spatial
separ
subsequ
fluoresc
abz
function
quench
detect
compound
necessari
use
activ
assay
proteinas
could
adapt
autom
system
ideal
assay
would
work
kinet
data
use
abztyr
substrat
time
scale
sever
minut
facilit
primari
data
correct
inner
filter
effect
rapid
evalu
thousand
potenti
inhibitor
adjust
essenti
observ
homogen
eas
autom
even
rel
low
concentr
substrat
sensit
minim
background
signal
fluoresc
cleav
product
signifipres
compound
test
quench
fluorescantli
quench
nitrotyrosin
moieti
intact
cenc
reson
energi
transfer
fret
assay
substrat
becom
common
tool
monitor
proteinas
activ
k
abztyr
substrat
pro
fulfil
necessari
criteria
use
effici
figur
valu
compar
robust
highthroughput
screen
ht
campaign
seen
recent
nonlabel
peptid
basi
assay
modif
also
mimic
cleavag
site
natur
substrat
peptid
substrat
includ
fluoresc
label
pro
mm
impli
label
quencher
oppos
side
proteinas
cleavag
incorpor
fret
detriment
assosit
figur
use
substrat
activ
ciation
enzym
substrat
calcul
proteinas
measur
directli
without
need
valu
appar
k
cat
k
cat
k
label
addit
step
purifi
andor
character
substrat
min
mm
product
type
assay
also
benefici
permin
respect
also
similar
remit
enzymat
reaction
monitor
real
time
obtain
accur
reaction
rate
aspect
quenchedfret
assay
particularli
attract
sinc
evalu
activ
proteinas
term
rate
potenti
fals
neg
occur
screen
due
presenc
inher
fluoresc
compound
test
reduc
two
fluorogen
peptid
substrat
synthes
develop
continu
assay
pro
proteolyt
activ
base
fret
peptid
design
princip
sequenc
flank
pro
polyprotein
solubl
consider
peptid
incorpor
anthranilatenitrotyrosin
donoracceptor
pair
abz
prefer
substrat
ht
analysi
also
illustr
qualiti
screen
term
monomer
wherea
dimer
form
reproduc
duplic
set
data
enzym
believ
catalyt
compet
figur
also
indic
pro
appear
purpos
screen
desir
use
inhibit
degre
larg
number
comlowest
concentr
substrat
yield
reliabl
pound
cutoff
determin
hit
threshold
reproduc
signal
found
assay
use
set
residu
enzym
activ
order
focu
fluorogen
peptid
gave
strong
signal
potent
inhibitor
linear
vari
pro
concentr
figur
five
hundr
seventytwo
hit
hit
rate
enabl
us
screen
substrat
concentr
identifi
primari
screen
pro
well
k
advantag
identifi
preliminari
analys
hit
opt
restrict
inhibitor
compet
substrat
enzym
number
compound
enter
secondari
screenact
site
therefor
like
spe
seri
virtual
experiment
filter
cific
toward
pro
hit
first
classifi
recurs
partit
compound
librari
use
screen
pro
contain
group
base
similar
molecular
small
molecul
averag
molecular
mass
structur
activ
primari
screen
gmol
particular
collect
screen
within
group
compound
strongli
high
qualiti
divers
druglik
inhibit
pro
chosen
repres
candiresuppli
avail
past
success
target
date
studi
secondari
analys
dose
campaign
run
duplic
respons
curv
repres
compound
micropl
format
fulli
autom
system
determin
use
standard
assay
condit
statist
paramet
describ
substrat
pro
test
measur
qualiti
ht
campaign
decompound
doserespons
relationship
comfin
pound
result
typic
sigmoid
semilogarithm
curv
associ
desir
inhibitor
com
pound
result
typic
curv
filter
elimin
nonspecif
inhibitor
effect
standard
deviat
averag
high
low
control
remain
compound
pro
activ
presenc
bovin
serum
albumin
bsa
determin
valu
reflect
error
associ
control
screen
well
size
hit
winif
degre
inhibit
pro
compound
decreas
presenc
bsa
inhibit
like
dow
figur
greater
indic
qualiti
screen
welldefin
hit
window
target
exclus
toward
pro
socal
promiscu
inhibitor
like
form
aggreg
primari
screen
sarscov
pro
two
replic
indic
assay
solut
nonspecif
absorb
adsorb
target
enzym
three
compound
show
use
detect
activ
pro
robust
amen
ht
replic
plot
residu
enzym
activ
mark
reduct
enzym
inhibit
presenc
bsa
greatest
effect
decreas
though
render
compound
unlik
drug
candid
may
use
studi
activ
compound
remov
prospect
inhibitor
pool
site
architectur
pro
remain
candid
inhibitor
inhibitori
action
remain
potenti
candid
predomin
compound
least
one
potenti
reacsignificantli
affect
inclus
mm
dtt
select
character
tive
center
tabl
thiol
side
chain
activ
site
cystein
pro
necessarili
good
nucleophil
doserespons
curv
five
compound
pro
yield
ic
valu
figur
therefor
capac
combin
varieti
electrophil
function
form
coval
adduct
evalu
select
compound
investig
abil
inhibit
four
proteinas
reaction
basi
sever
class
exist
peptid
inhibitor
cystein
proteas
includ
vari
structur
mechanist
related
sarscov
pro
hepat
viru
hav
pro
like
keton
ester
amid
long
recogn
reactiv
toward
thiol
gener
titi
c
nonstructur
proteinas
pro
chymotrypsin
serin
proteas
two
cystein
proteas
particular
two
identifi
sulfur
contain
compound
tabl
also
fold
pro
final
papain
paradigm
cystein
proteinas
activ
site
cyshisasp
cacap
form
disulfid
linkag
catalyt
thiol
pro
inactiv
enzym
retalyt
triad
whose
structur
fold
resembl
share
chymotrypsin
pro
pro
pro
main
carbonyl
function
correspond
nitrogenand
sulfurcontain
analog
list
tabl
difficult
case
obtain
full
doserespons
curv
everi
inhibitor
may
also
enough
electrophil
charact
promot
nucleophil
attack
activ
site
thiol
teinas
due
interf
compound
fluoresc
compound
insolubl
assay
condiof
pro
due
potenti
inher
reactiv
candid
inhibitor
sought
identifi
elimin
tion
case
lack
data
higher
compound
concentr
preclud
interpol
relithos
compound
whose
high
reactiv
render
nonspecif
toward
activ
site
pro
includ
abl
ic
valu
ic
report
lower
limit
tabl
altern
compound
enzym
lthreitol
dtt
inhibit
reaction
reduct
inhibit
pro
candid
inhibit
seen
highest
concentr
test
indic
accordingli
import
note
compound
presenc
dtt
suggest
compound
would
probabl
react
nonspecif
absenc
full
mechanist
analys
ic
valu
intend
reveal
profound
differ
biolog
avail
thiol
function
alconsid
mechanist
structur
relationship
pro
hav
pro
lesser
extent
pro
interest
learn
compound
show
highest
activ
relat
enzym
addit
inhibit
pro
ic
also
demonstr
interest
select
profil
good
activ
sarscov
pro
ic
valu
respect
detect
inhibit
proteinas
test
particular
compound
howev
prove
difficult
assay
hav
pro
pro
due
background
fluoresc
could
test
concentr
greater
nevertheless
detect
inhibit
seen
concentr
indic
ic
molecul
would
necessarili
much
higher
proteas
select
data
therefor
point
two
molecul
appar
select
pro
may
well
promis
lead
mechanist
character
optim
effort
toward
proteasebas
antivir
sarscov
one
molecul
interest
select
picornavirallik
proteinas
could
prove
viabl
lead
famili
proteolyt
enzym
yeast
ic
mm
studi
examin
inhibit
isomeras
seri
substitut
potenc
provid
insight
select
benzothiazol
indic
interinhibitor
aid
priorit
lead
act
cystein
residu
enzym
continu
studi
previous
shown
central
dimer
incompound
show
least
select
teract
although
yet
uncharacter
report
respect
pro
ic
perturb
contact
interfac
subunit
inhibitor
capabl
inactiv
proteinas
homodim
inactiv
enzym
therefor
quit
studi
although
respons
pro
ic
possibl
associ
activ
site
significantli
lower
enzym
cystein
pro
similar
manner
disrupt
show
select
toward
prolyt
activ
exact
mechan
inhibit
pro
teinas
chymotrypsinlik
fold
seen
remain
secondari
hit
requir
inhibit
pro
ic
hav
pro
ic
studi
character
order
evalu
chymotrypsin
ic
although
effect
potenti
act
lead
develop
seen
pro
also
share
structur
novel
therapeut
sarscov
potenti
motif
papain
lack
fold
unaffect
picornavirallik
proteinas
addit
import
differ
pro
core
structur
compound
chemic
pro
coronavir
enzym
function
modifi
improv
key
physic
properti
activ
dimer
wherea
pro
activ
monom
potenc
solubl
vitro
interact
pro
subunit
clearli
evid
pro
screen
campaign
suffici
weak
disrupt
dimer
interha
gener
wealth
data
mine
face
propos
promis
target
novel
number
studi
intent
identifi
antivir
agent
view
related
novel
small
molecul
would
lead
pro
hav
pro
therefor
like
five
ment
therapeut
effect
sarscov
secondari
hit
also
activ
toward
hav
result
gener
screen
campaign
pro
interact
pro
dimer
interfac
appli
type
studi
pro
relat
proteinas
includ
picornavir
pro
end
site
common
proteinas
peptid
pro
well
conpolymeras
roch
appli
scienc
accord
manufacturtain
high
low
control
neat
dmso
ad
instead
er
condit
use
anneal
temperatur
reof
librari
compound
includ
micropl
buffer
sult
amplicon
digest
use
bsmi
hindiii
use
ad
reaction
instead
pro
low
control
primari
replac
correspond
fragment
yield
hit
defin
compound
reduc
activ
whose
nucleotid
sequenc
confirm
describ
pro
half
averag
residu
activ
high
control
